Logo
x

Search

Subscribe Now

Attralus

Attralus’ 124I-Evuzamitide (AT-01) Gains the US FDA’s Breakthrough Therapy Designation for the Diagnosis of Cardiac Amyloidosis

Attralus’ 124I-Evuzamitide (AT-01) Gains the US FDA’s Breakthrough Therapy Designation for the Diagnosis of Cardiac Amyloidosis

  • August 5, 2024
Attralus Published Results from 2 Studies for 124I-Evuzamitide in the Journal of American College of Cardiology

Attralus Published Results from 2 Studies for 124I-Evuzamitide in the Journal of American College of Cardiology

  • November 8, 2023
Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

  • May 30, 2023
Attralus Entered into Option and License Agreement with Ossianix to Deliver AT-04 for the Treatment of Neurodegenerative Disorders

Attralus Entered into Option and License Agreement with Ossianix to Deliver AT-04 for the Treatment of Neurodegenerative Disorders

  • November 18, 2022
Jonathan Wall, Co-founder & Interim CSO at Attralus Share Insights from its New Data Presented across its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Jonathan Wall, Co-founder & Interim CSO at Attralus Share Insights from its New Data Presented across its Amyloidosis Portfolio at...

  • October 17, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.